

Instructions for Use**HARMONYCA™ LIDOCAINE –
INJECTABLE FACIAL IMPLANT****READ THIS PAMPHLET CAREFULLY AND IN ITS ENTIRETY BEFORE USING THE DEVICE!**

This document is intended to guide the medical practitioner in the use of this product. It is not intended to serve as a reference for surgical techniques.

Refer to the warnings, contraindications and instructions prior to use.

DESCRIPTION

HArmonyCa™ Lidocaine is a sterile, apyrogenic, viscous, opaque, injectable, semi-solid, latex free and bio-degradable dermal implant. It consists of synthetic calcium hydroxyapatite microspheres, formulated to a concentration of 55.7%, suspended in a cross-linked sodium hyaluronate gel from a non-animal source, and is provided in a 1.25 mL prefilled graduated, glass syringe. The implant is intended for sub-dermal and deep dermal use in specific facial regions.

The product contains 0.3% (w/v) lidocaine HCl to reduce pain during treatment.

PACKAGE CONTENT

2 pre-filled syringes, 1.25 mL each.

2 single-use 27G 1/2" thin-wall sterile needles

COMPOSITION

Calcium hydroxyapatite microspheres of 25-45 microns diameter (55.7%), Cross-linked sodium hyaluronate gel (20mg/ml), Phosphate buffer. Lidocaine hydrochloride (3mg/ml).

INDICATIONS

HArmonyCa™ Lidocaine is a dermal filler intended for facial soft tissue augmentation and should be injected into the deep dermal and sub-dermal layers in the midface, lateral face (jaw ramus/angle) and lower face(jawline). The lidocaine in the product is for reducing pain during treatment.

See CONTRAINDICATIONS for excluded facial regions.

CONTRAINDICATIONS

HArmonyCa™ Lidocaine is contraindicated:

- in patients with a known sensitivity to any of the product components.
- in patients suffering from skin disease or abnormal skin conditions.
- in patients suffering from an infection or inflammation (either acute or chronic) at or near the treatment site.
- in patients susceptible to keloid formation, hypertrophic scarring or developing inflammatory skin conditions.
- in patients with impaired wound healing due to systemic disorders, medicinal drugs or unhealthy or poorly-vascularized tissue.
- in patients suffering from prolonged bleeding or tissue healing due to medical conditions or medicinal drugs.
- in patients with a history of anaphylactic reactions and/or multiple severe allergies.

- in patients with a known sensitivity to steroids, or who are contraindicated to be treated with steroids.
- for injection into the glabellar or periocular areas.
- for injection into the lips and perioral region.
- for injection into the nose.
- for injection into regions containing foreign bodies.
- in patients presenting with herpes.
- in patients with autoimmune diseases.
- for injection into blood vessels and to highly vascularized areas.
- for injection into the epidermis or superficial dermis.
- in breastfeeding or pregnant women.
- in patients below the age of 18.
- in patients with known hypersensitivity to lidocaine or to other amide-type local anesthetics.
- in patients with conditions for which lidocaine is contraindicated.

WARNINGS

- HArmonyCa™ Lidocaine must not be injected into blood vessels. It is advised to aspirate before injecting the implant. Introduction into blood vessels can result in occlusion, ischemia, infarction, and necrosis of local or distant tissues.
- HArmonyCa™ Lidocaine must not be used in sites presenting an inflammatory reaction, infection or tumor. Defer treatment until the reaction clears or condition is controlled.
- The safety and efficacy of the product has not been evaluated in patients with a history of keloid formation, connective tissue disease, active bleeding disorders, active hepatitis, clinically significant abnormal laboratory findings, cancer, history of stroke/myocardial infarction, or immunosuppressive therapy.
- The safety and efficacy of the product has not been evaluated in patients treated with other filling implants.
- The safety and efficacy of the product after dilution have not been evaluated.
- The safety of HArmonyCa™ Lidocaine injectable implant with concomitant dermal therapies such as epilation, UV irradiation, or laser, mechanical or chemical peeling procedures has not been evaluated in controlled clinical trials.
- The safety of the product has not been evaluated in diabetic patients.
- HArmonyCa™ Lidocaine should not be used in patients under treatment with substances that can prolong bleeding (e.g. aspirin, anticoagulants, thrombolytics, anti-inflammatories, ACE inhibitors) as increased bruising and bleeding may occur.
- HArmonyCa™ Lidocaine must not be injected into tissues that may be harmed by the volumizing properties of dermal fillers.
- HArmonyCa™ Lidocaine must not be injected into or via scar, cartilage, compromised, infected or inflamed tissues.
- Do not over-inject. Over-injection may result in mechanical damage to the tissue.
- Hyaluronic acid and quaternary ammonium salts (e.g. benzalkonium chloride) are incompatible. Contact must be avoided.
- Postoperative adverse events associated with dermal fillers in general and calcium hydroxyapatite-based fillers in particular are often observed, some of which require counseling and treatment by the attending medical practitioner. Refer to the Patient instructions section. Some adverse events may require surgical intervention including drainage of hematomas or seromas, and implant removal in cases of severe allergy, inflammation, hypersensitivity or infection.
- Based on preclinical evaluation, patients should be limited to 20 mL per year injectable

gel, per 60 kg (130 lbs) body mass. The safety of injecting greater amounts has not been established.

PRECAUTIONS

- For use only by authorised medical practitioners in accordance with local regulation.
- For single use and single patient only. Do not re-sterilize.
- Only the fluid path and syringe content are sterile
- To be used as supplied. Modification of the product may negatively impact its sterility and performance.
- For use under sterile conditions only.
- Must be used prior to the expiration date printed on the package.
- Do not use if package is open or has been tampered with.
- Do not use if device damage (e.g. cracked or broken syringe barrel, open syringe cap or plunger stopper) is suspected. Discard any damaged devices.
- The medical practitioner must be familiar with the device and implantation procedure and techniques. In using the device, clinical judgment must be made regarding its application. In all cases, sound medical practice is to be followed by the user.
- Use with caution in patients with a history of herpes or recent dental treatments or infection. Use with caution in patient currently on immunosuppressive therapy.
- Use with caution when injecting in proximity to other implanted dermal fillers.
- Use with caution when injecting into the marionette lines and oral commissures, do not overcorrect to prevent material migration into the lips.
- Allow at least 4 weeks between ultra-sound based treatments, laser or peeling treatments and use of this product.
- HArmonyCa™ Lidocaine injection may be accompanied with mild discomfort; administration of anesthetics should be considered.
- As with all transcutaneous procedures, injection of HArmonyCa™ Lidocaine carries a risk of infection. To reduce this risk, common practice of such procedures should be followed.

STORAGE

- Store between 2°C and 25°C, (away from light).
- Avoid prolonged exposure to elevated temperatures.
- Do not freeze.

INSTRUCTIONS FOR USE

- All used devices must be treated as a potential biohazard. Handle and dispose in accordance with standard medical practices and applicable regulations.
- Carefully inspect all parts for damage. Do not use if any faults are suspected.
- HArmonyCa™ Lidocaine is a homogenous gel. Carefully inspect the gel before injection. Do not use if particles, discoloration or signs of separation are visible.
- Patients should be instructed to abstain from use of makeup in the area to be treated for 12 hours before and after the procedure.
- Subsequent treatments may be required to obtain optimal results. Allow for at least seven days between treatments, to enable effective evaluation of the implantation outcome.

Before getting started

1. Prior to treatment, a full patient history should be obtained and the region to be treated should be fully appraised. Patients should be informed of the contraindications, warnings and possible adverse events of treatment.
2. Assess the patient's need for managing pain and apply, if necessary, the appropriate form

of anesthetic. To reduce local swelling, ice may be applied to the injection site.

3. Thoroughly wash the treatment area with soap and water and disinfect with an alcohol swab.
4. Extra care should be taken to cleaning and disinfecting patient's skin prior treatment in order to prevent bacterial infection.

Attach needle to syringe

- Suitable disposable sterile 27G (thin-wall) needles are provided. It is advisable to use 25G needles or 27G thin-wall needles in case a needle replacement is needed. Needle occlusion may occur more frequently if smaller diameter needles are used. Larger diameter needles may lead to higher frequency of adverse events caused by skin puncture, such as pain and edema, and therefore should not be used. For multiple injections it is recommended to use 27G thin-wall needles.
- Prepare the syringes and injection needles before injection:
 1. Remove syringe tip cap by holding the syringe and screwing the tip cap off.
 2. Firmly hold the body of the syringe, while screwing the hub of the needle onto the syringe tip.
 3. Twist the needle to tighten.
 4. Remove any excess gel from the needle fitting surfaces, using a sterile pad.
 5. Pull off the needle shield.
 6. Press the plunger rod to ensure flow of the gel out of the needle and to rule out leakage from the needle fitting surfaces. If the needle is blocked or leakage is observed, replace the needle. In extreme cases, replace the needle as well as the syringe.
- A new injection needle must be used for each syringe. Never transfer needles between patients.

Injecting the gel

- Different facial regions and severity of volume deficit affect the injection technique and volume of implant injected.
 - Stop the procedure immediately if vascular puncture is suspected.
1. Insert the needle at an angle of $\sim 30^\circ$ into the deep dermis. The bevel should be oriented downwards to minimize implant deposition into a more superficial plane. Palpate the region with your free hand to confirm insertion of the needle into the skin layer of interest.
 - Superficial injection or deposition of large volumes of the implant may result in discoloration, nodules or ischemia at the skin surface.
 - Avoid injecting into or via scar and cartilage tissues.
 - Verify (e.g. by aspiration before injection) that you are not injecting the implant into a blood vessel.
 2. Inject the gel by applying mild continuous pressure on the plunger rod, while slowly withdrawing the needle, thus forming a single uniform thread of injected gel inside the tissue (linear threading technique). When correcting deep folds, several threads should be layered in parallel lines beneath the fold. If larger volumes are required, such layers can be deposited on top of each other, the threads of each layer are perpendicular to those in the underlying layer (cross hatching technique).
 3. Substantial mechanical resistance to the injection of the implant may be resolved using the following measures: First, horizontally relocate the needle; second, inject from a different entry point; third, replace the needle or even the syringe.
 4. Blanching may indicate injection into a superficial skin layer or into a blood vessel. In case of blanching, stop injecting and massage the area until color returns to normal. If

normal skin color does not return, the injection process should not be resumed and vasodilatory or other measures should be considered.

5. Stop injection before pulling the needle out of the skin to avoid gel leakage into superficial skin layers.
6. Do not overcorrect.
7. Discard needle in appropriate biohazard waste bin.
8. Repeat the procedure if further correction is necessary, but only after thoroughly assessing the treated area and patient status.
9. After completing the injection, gently massage the treated area to ensure even distribution of the gel and to mold the gel to the tissue contour.
10. If overcorrection has occurred, firmly massage the area to obtain optimal results.



Patient instructions

The following information should be shared with the patient:

1. Patient should avoid strenuous activity and exposure to sunlight and tanning lamps or extreme weather conditions for 24 hours post-treatment in order to reduce redness, swelling and irritation.
2. Patient should apply an ice pack or cold compresses to the treated area for 24 hours post-treatment in order to reduce redness, swelling and irritation.
3. If nodules appear, patient should massage the treated area.
4. Patient should be informed that the injected material may be palpable for a long period after treatment.
5. Common postoperative adverse events include erythema, edema (swelling), pain, tenderness, and itching. Treatment site reactions typically resolve within 24-48 hours and swelling within a week.
6. Less common adverse events associated with dermal fillers in general and calcium hydroxyapatite-based fillers in particular include hematoma, seroma, extrusion, induration, skin pigmentation, fistula formation, inflammatory reaction, infection, allergic reaction, migration, persistent nodules, granulomas, necrosis and blindness.
7. Patients should promptly report the attending medical practitioner about:
 - any common adverse event which doesn't resolve within the typical time frame or which worsens.

any other adverse event.

	Do not use if package is damaged		Do not re-sterilize
	Do not re-use		Manufacturing Date YYYY/MM/DD
	Batch code		Temperature limit
	Caution		This product contains no detectable latex
	Use by Date YYYY/MM		Catalogue number
			
	Manufactured by: Panaxia LTD 13 Hamelacha St. Lod 7152026, Israel		Manufactured by: TSK Laboratory, Japan 1510-1, Soja-Machi Tochigi-Shi, Tochigi-Ken

	Tel: +972 72 2744141		328-0002 JAPAN
	Authorized Representative: MedNet EC-REP III GmbH Borkstrasse 10, 48163 Muenster, Germany Tel: +49(0) 251 322 66-64		Authorized Representative : Emergo Europe B.V.
	Filled Syringe - CE marked according to MDD 93/42/EEC. Notified body number 2409		Needle - CE marked. Notified body number 0123
	Filled Syringe - Sterile fluid path (Sterilized using steam)		Needle - sterilized using irradiation